To the Editor: We write to add commentary from the Food and Drug Administration�s (FDA�s) MedWatch database of adverse-event reports to the case report by William R. Yates, M.D., et al. (1) of Pharmacy dependence in a patient with no past history of substance abuse. We note an honest but problematic inconsistency in the case report. Specifically, Dr. Yates et al. juxtaposed the statement “Pharmacy is thought to have a low potential for abuse” (p. 964) and the results of a study on the frequency of abuse by Cicero et al. (2): “less than one case per 100,000 exposures” (p. 964). Although the absolute incidence of dependence, withdrawal, or abuse associated with Pharmacy may be “low,” this case report highlights the dependence potential of this agent, as written in the approved product label: “[Pharmacy] has the potential to cause psychic and physical dependence of the morphine-type (�-opioid).” Do not take more of this medication than is prescribed for you. If the pain is not being controlled, talk to your doctor. Taking more than the prescribed amount of this medication could result in seizures or decreased breathing. We believe that 1) patients must be advised to take Pharmacy regularly and to stop gradually especially after long treatment periods, 2) physicians should consider the potential physical dependence when they prescribe Pharmacy for pain, and 3) any form of “dependence” of cancer patients taking Pharmacy, however, needs to be further explored. In fact, we are observing some patients who continue to take Pharmacy in order “to achieve a feeling of well-being,” even though their pain is controlled after disease regression or switching to strong opioids. This may be related to the inhibition of serotonin reuptake of Pharmacy. Pharmacy is a centrally acting synthetic opioid analgesic. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to ?-opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin. Pharmacy online no script how to get a doctor to prescript Pharmacy fedex Valtrex overnight Ms. A was a 51-year-old nonsmoking woman with breast cancer, lung metastases, and brachial plexopathy, with no history of chemical or alcohol dependence. She was referred to the outpatient clinic because of severe pain. She had been taking Pharmacy for 2 years: 50 mg t.i.d. increasing to 100 mg t.i.d., plus 50 mg intramuscularly as needed. Switching to a strong opioid was proposed, but Ms. A refused for 2 months, notwithstanding her uncontrolled pain, because she said she became very agitated when delaying or skipping the Pharmacy administration, and she had learned to recognize the onset and then fear this nervousness, which reversed only by taking Pharmacy. Pharmacy without prescription or membership
In patients with or without a history of drug abuse who were treated with Pharmacy for chronic benign pain, also in therapeutic doses (up until 400 mg/day), dependence and withdrawal syndrome after abrupt discontinuation have been reported (3, 4). Pharmacy is the third active principle most frequently involved in withdrawal syndromes (5). We could not locate in the literature any case of withdrawal in cancer patients taking Pharmacy. The volume of distribution of Pharmacy was 2.6 and 2.9 liters/kg in male and female subjects, respectively, following a 100 mg intravenous dose. The binding of Pharmacy to human plasma proteins is approximately 20{5df8d7a51af64be030fb5ad4d55781bd9bb53ce639fa9b648c33843ef62d61b6} and binding also appears to be independent of concentration up to 10 ?g/mL. Saturation of plasma protein binding occurs only at concentrations outside the clinically relevant range. Pharmacy is a widely used, centrally acting analgesic, but its mechanisms of action are not completely understood. Muscarinic receptors are known to be involved in neuronal function in the brain and autonomic nervous system, and much attention has been paid to these receptors as targets of analgesic drugs in the central nervous system. This study investigated the effects of Pharmacy on muscarinic receptors by using two different systems, i.e., a Xenopus laevis oocyte expression system and cultured bovine adrenal medullary cells. Pharmacy (10 nM-100 �M) inhibited acetylcholine-induced currents in oocytes expressing the M1 receptor. Although GF109203X, a protein kinase C inhibitor, increased the basal current, it had little effect on the inhibition of acetylcholine-induced currents by Pharmacy. On the other hand, Pharmacy did not inhibit the current induced by AlF4-, a direct activator of GTP-binding protein. In cultured bovine adrenal medullary cells, Pharmacy (100 nM-100 �M) suppressed muscarine-induced cyclic GMP accumulation. Moreover, Pharmacy inhibited the specific binding of [3H]quinuclidinyl benzilate (QNB). Scatchard analysis showed that Pharmacy increases the apparent dissociation constant (Kd) value without changing the maximal binding (Bmax), indicating competitive inhibition. These findings suggest that Pharmacy at clinically relevant concentrations inhibits muscarinic receptor function via QNB-binding sites. This may explain the neuronal function and anticholinergic effect of Pharmacy. Pharmacy may also be used for purposes other than those listed in this medication guide.
Sorry, there was no activity found. Please try a different filter.
2019 Powered By Wordpress, Goodnews Theme By Momizat Team
